591 related articles for article (PubMed ID: 33052220)
1. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
2. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
3. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
4. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
Cheal SM; Xu H; Guo HF; Zanzonico PB; Larson SM; Cheung NK
Mol Cancer Ther; 2014 Jul; 13(7):1803-12. PubMed ID: 24944121
[TBL] [Abstract][Full Text] [Related]
6. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
Orcutt KD; Slusarczyk AL; Cieslewicz M; Ruiz-Yi B; Bhushan KR; Frangioni JV; Wittrup KD
Nucl Med Biol; 2011 Feb; 38(2):223-33. PubMed ID: 21315278
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of HER2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract][Full Text] [Related]
9. Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle Radiation.
Shah MA; Zhang X; Rossin R; Robillard MS; Fisher DR; Bueltmann T; Hoeben FJM; Quinn TP
Bioconjug Chem; 2017 Dec; 28(12):3007-3015. PubMed ID: 29129050
[TBL] [Abstract][Full Text] [Related]
10. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
11. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
[No Abstract] [Full Text] [Related]
12. Leveraging Bioorthogonal Click Chemistry to Improve
Poty S; Carter LM; Mandleywala K; Membreno R; Abdel-Atti D; Ragupathi A; Scholz WW; Zeglis BM; Lewis JS
Clin Cancer Res; 2019 Jan; 25(2):868-880. PubMed ID: 30352909
[TBL] [Abstract][Full Text] [Related]
13.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
14. Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.
Chandler CS; Bell MM; Chung SK; Veach DR; Fung EK; Punzalan B; Burnes Vargas D; Patel M; Xu H; Guo HF; Santich BH; Zanzonico PB; Monette S; Nash GM; Cercek A; Jungbluth A; Pandit-Taskar N; Cheung NKV; Larson SM; Cheal SM
Mol Cancer Ther; 2022 Jan; 21(1):125-137. PubMed ID: 34667111
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
[TBL] [Abstract][Full Text] [Related]
16. An
Cheal SM; Patel M; Yang G; Veach D; Xu H; Guo HF; Zanzonico PB; Axworthy DB; Cheung NV; Ouerfelli O; Larson SM
Bioconjug Chem; 2020 Mar; 31(3):501-506. PubMed ID: 31891487
[TBL] [Abstract][Full Text] [Related]
17. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
[TBL] [Abstract][Full Text] [Related]
18. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
20. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Schoffelen R; Woliner-van der Weg W; Visser EP; Goldenberg DM; Sharkey RM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1593-602. PubMed ID: 24643780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
